

April 15, 2015



Navidea Announces Lymphoseek® Presentations at Upcoming Medical Conferences

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced that Lymphoseek® (technetium Tc 99m tilmanocept) injection data are scheduled for presentations at the following conferences: American Society of Breast Surgeons 16th Annual Meeting in Orlando, FL, and 2015 American Head & Neck Society Annual Meeting & Translational Research Meeting, held during the Combined Otolaryngology Spring Meetings (COSM) in Boston, MA. Details of the presentations are listed below.

2015 American Head & Neck Society Annual Meeting & Translational Research Meeting, held during the Combined Otolaryngology Spring Meetings (COSM)

April 21 - 23, 2015 Boston, MA

Session Type: Oral

Date: April 22, 2015

Title: Pivotal Phase 3 Trial Results of 99mTc-Tilmanocept in Sentinel Lymph Node Detection in Oral Cancer Patients: Comparison of "Same Day" vs "Next Day" imaging and diagnostic efficacy in floor of mouth disease

Authors: Stephen Y. Lai^{1*}, Amit Agrawal², Frank Civantos³

¹M.D. Anderson Cancer Center, Houston, TX; ²The Ohio State University Wexner Medical Center, Columbus, OH;

³University of Miami Hospital, Miami, FL

*Presenter

American Society of Breast Surgeons 16th Annual Meeting

April 29 – May 3, 2015 Orlando, FL

Session Type: Oral

Date: May 2, 2015

Title: Sentinel node mapping with 99mTc-tilmanocept: clinical trial results and follow-up data show consistent performance across studies and tumor types

Authors: Anne Wallace¹, Jennifer Baker^{2*}

¹Plastic Surgery, University of California - San Diego, San Diego, CA; ²Department of Surgery, University of California - San Diego, San Diego, CA

*Presenter

About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. Navidea is developing multiple precision-targeted products and platforms including Manocept™, NAV4694, and NAV5001, to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea's first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals

Investors

Tom Baker, 617-532-0624

tbaker@navidea.com

or

Media

Sharon Correia, 978-655-2686

Associate Director, Corporate Communications

Source: Navidea Biopharmaceuticals, Inc.